Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2012

View Archived Issues

FDA extends review of Eliquis NDA

Aastrom Biosciences kicks off enrollment in REVIVE study

Novel AstraZeneca antibacterials inhibit bifunctional protein

New calcium-activated potassium channel blocker shows potential in IBD model

Novel plasma kallikrein inhibitors divulged by Novartis

Brazilian university patents new vaccines for brucellosis prevention

Nippon Chemiphar develops novel agents with analgesic potential

New potential Alzheimer's disease therapies designed in China

Amylin Pharmaceuticals presents novel glucagon GLP-1 receptor agonists

Cadila Healthcare investigators identify new PARP-1 inhibitors

First four-strain flu vaccine approved in U.S.

Promising phase Ib data reported on QLT-091001

Bavarian Nordic submits MAA for smallpox vaccine

Phase II BI-204 trial reaches full enrollment

Senesco adds second trial site to evaluate SNS01-T in multiple myeloma

Taiho Pharmaceutical files application to expand Abraxane indications in Japan

NME efficiently activates type I natural killer T cells

Helsinn initiates proof-of-concept study of elsiglutide

Nymox studies BPH drug candidate in new indication

GSK and Daiichi Sankyo to form joint venture

Intercell starts second part of C. difficile vaccine candidate trial

FDA issues safety warning regarding statins

EryDel reports promising data from phase II EryDex trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...